Disease Landscape and Forecast Insights

With biosimilar infliximab approved in Europe and filed for approval in the United States, rheumatologists and gastroenterologists will soon have the opportunity to prescribe biosimilars to their…

Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe…

This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on anemia management (…

Type 2 diabetes is a complex metabolic disorder characterized by a declining ability to produce or utilize insulin. The chronic and progressive nature of the disease, as well as its complications…

The use of biomarkers and personalized medicine is at a very early stage in asthma. Although most asthma patients can obtain disease control through treatment with available therapies, there…

Psoriatic arthritis (PsA) is an inflammatory joint disease that denotes a heterogeneous group of arthritides that may be present with or without obvious psoriatic lesions; therefore, treatment is…

Chronic kidney disease (CKD) affects approximately 26 million people in the United States. While there are multiple prescription therapies that are available for treating the associated symptoms,…

Gastric cancer is the fourth-most common malignancy in terms of incidence and is the third-most common cause of cancer-related death worldwide. Japan has the highest incidence of gastric cancer…

Last Updated 16 September 2014 Owing to its large population, the treatment of breast cancer remains an active area of research with a rich and diverse product pipeline. A competitive current…

The number of diagnosed acute heart failure (AHF) events and prevalent chronic heart failure (CHF) cases in the seven major markets that we cover is increasing annually, driven by changes in the…

Last Updated 12 September 2014 The type 2 diabetes therapy market will rapidly expand over our 2013-2023 study period, fueled by the disease’s increasing prevalence and a high unmet need for…

Gram-negative infections (GNIs) represent a high-value segment of the antibiotic market and are often treated in the hospital setting. Infections due to Gram-negative pathogens (GNPs) are…